ARS Pharmaceuticals Inc (SPRY)
8.17
+0.43
(+5.56%)
USD |
NASDAQ |
Jun 21, 16:00
8.17
0.00 (0.00%)
After-Hours: 16:14
ARS Pharmaceuticals Net Income (Quarterly): -10.29M for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -10.29M |
December 31, 2023 | -7.168M |
September 30, 2023 | -14.87M |
June 30, 2023 | -17.37M |
March 31, 2023 | -14.96M |
Date | Value |
---|---|
December 31, 2022 | -14.43M |
September 30, 2022 | -6.583M |
June 30, 2022 | -6.42M |
March 31, 2022 | -7.25M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-17.37M
Minimum
Jun 2023
-6.42M
Maximum
Jun 2022
-11.04M
Average
-10.29M
Median
Mar 2024
Net Income (Quarterly) Benchmarks
KalVista Pharmaceuticals Inc | -29.03M |
Phathom Pharmaceuticals Inc | -82.85M |
Vera Therapeutics Inc | -28.38M |
Nuvalent Inc | -44.48M |
CEL-SCI Corp | -7.245M |
Net Income (Quarterly) Related Metrics
Total Expenses (Quarterly) | 13.19M |
EPS Diluted (Quarterly) | -0.11 |
Enterprise Value | 526.34M |
Earnings Yield | -6.36% |
Normalized Earnings Yield | -6.901 |